Literature DB >> 9690515

MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.

W Lutz1, S Fulda, I Jeremias, K M Debatin, M Schwab.   

Abstract

Neuroblastomas undergo spontaneous regression at an unusually high rate. The mechanisms are not clear, but apoptosis may be involved. A large proportion of neuroblastomas is characterized by amplification of MYCN. Using human neuroblastoma cells harbouring tetracycline controlled expression of MYCN we have analysed the role of the MycN protein and IFNgamma in cell death decision. Neither conditional expression of MYCN nor treatment with IFNgamma alone was sufficient to trigger cell death. However, when acting in concert MycN and IFNgamma efficiently triggered cell death, which was accompanied by DNA fragmentation and required caspase activity, two hallmarks of apoptosis. MycN and IFNgamma may cooperate along at least two different pathways. First, IFNgamma increased the CD95 cell surface expression while MycN enhanced the cellular susceptibility for the CD95 mediated death signal. Second, IFNgamma treatment induced expression of BAK mRNA while MycN and IFNgamma in combination increased the amount of Bax protein, another activator of apoptosis, without a concomitant increase in BAX mRNA. MycN also increased cell death in response to TRAIL and TNFalpha, suggesting that enforced MYCN expression in general increases the susceptibility of neuroblastoma cells towards a variety of death stimuli.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690515     DOI: 10.1038/sj.onc.1200201

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

2.  Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.

Authors:  Hongjuan Cui; Bo Hu; Tai Li; Jun Ma; Goleeta Alam; William T Gunning; Han-Fei Ding
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

3.  Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

Authors:  M Stacey Ricci; Zhaoyu Jin; Michael Dews; Duonan Yu; Andrei Thomas-Tikhonenko; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

4.  CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Authors:  Sina Gogolin; Volker Ehemann; Gabriele Becker; Lena M Brueckner; Daniel Dreidax; Steffen Bannert; Ingo Nolte; Larissa Savelyeva; Emma Bell; Frank Westermann
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

5.  N-myc modulates expression of p73 in neuroblastoma.

Authors:  Xiaoxiang Zhu; Katharina Wimmer; Rork Kuick; Barbara J Lamb; Stephanie Motyka; Rama Jasty; Valerie P Castle; Samir M Hanash
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

6.  Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.

Authors:  Sebastian Luci; Beatrice Giemsa; Gerd Hause; Holger Kluge; Klaus Eder
Journal:  BMC Pharmacol       Date:  2007-04-16

7.  TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.

Authors:  Koen Mo Galenkamp; Paulina Carriba; Jorge Urresti; Laura Planells-Ferrer; Elena Coccia; Joaquín Lopez-Soriano; Bruna Barneda-Zahonero; Rana S Moubarak; Miguel F Segura; Joan X Comella
Journal:  Mol Cancer       Date:  2015-03-19       Impact factor: 27.401

8.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.

Authors:  Frank Westermann; Daniel Muth; Axel Benner; Tobias Bauer; Kai-Oliver Henrich; André Oberthuer; Benedikt Brors; Tim Beissbarth; Jo Vandesompele; Filip Pattyn; Barbara Hero; Rainer König; Matthias Fischer; Manfred Schwab
Journal:  Genome Biol       Date:  2008-10-13       Impact factor: 13.583

9.  Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.

Authors:  Marialaura Petroni; Veronica Veschi; Alberto Gulino; Giuseppe Giannini
Journal:  Front Oncol       Date:  2012-10-12       Impact factor: 6.244

10.  BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas.

Authors:  Katrin Nowak; Kornelius Kerl; Daniel Fehr; Christoph Kramps; Christine Gessner; Katrin Killmer; Birgit Samans; Bernd Berwanger; Holger Christiansen; Werner Lutz
Journal:  Nucleic Acids Res       Date:  2006-03-31       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.